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Severe hemorrhage from injury claims the lives of nearly 50,000 Americans every year. Because many of these deaths occur in young, vital peo ple, this number translates to an astounding loss of almost 2,000,000 years of productive life. 1 Recent studies indicate that performing tempo rizing measures to control bleeding, minimizing factors that exacerbate hemorrhage, and shorten ing the time to definitive hemostasis may prevent some of these deaths, but more research is need ed.
2 Because most deaths occur within 2 hours after an injury, severe hemorrhage is the ulti mate timesensitive condition.
Many different approaches have been taken to solve this vexing problem. The landmark study by Bickell et al. 3 involving patients with penetrat ing injuries of the torso showed that withhold ing preoperative crystalloid solution was superior to using goaldirected, crystalloidbased therapy in an urban environment. Rapid transport of these patients -even by police rather than by emergency medical services -is essential. 4 Moreover, in patients with severe hemorrhage of the arms or legs, prehospital application of a tourniquet is both safe and beneficial.
5
But what about patients who have blunt inju ries and longer transport times? The options for preventing further hemorrhage, replacing blood loss, and bolstering the body's hemostatic path ways in these patients remain limited. Military antishock trousers designed to augment proxi mal perfusion while limiting ongoing hemor rhage have been shown to be ineffective and potentially even harmful. More recently, the Re suscitation Outcomes Consortium evaluated vari ous options for prehospital crystalloid and colloid resuscitation, but this study was halted early for futility and for possible harm to patients who did not receive blood. 6 However, in this issue of the Journal, the investigators in the Prehospital Air Medical Plasma (PAMPer) trial 7 report on a generalizable intervention that appears to im prove survival in patients with trauma who are bleeding and at risk for hemorrhagic shock: prehospital plasma resuscitation.
Of course, delivering hemostatic resuscitation to patients who are bleeding as soon as possible after injury makes intuitive sense. During World War II, freezedried plasma was administered routinely in the prehospital setting.
8 Unfortu nately, in many cases, this "field plasma" was the only blood product given, and it proved to be inadequate to save the lives of patients who were in severe hemorrhagic shock. More recently, the concept of "damagecontrol resuscitation" has emerged, wherein plasma, platelets, and red cells are transfused in nearly equal proportions and administration of nonhemostatic crystalloid solu tion is minimized. This approach has clearly im proved outcomes in patients who survive trans port to the trauma center, 9 which begs the question of whether damagecontrol resuscitation could be started during transport.
A recent study of blood products adminis tered in the prehospital setting to combat casual ties during helicopter transport showed a sur vival benefit, 10 and now, the investigators of the PAMPer trial 7 have confirmed a similar benefit in severely injured civilian patients. In this prag matic, randomized, controlled trial, 230 patients with unstable vital signs were administered 2 units of plasma before any other resuscitation fluid (plasma group), and 271 patients with unstable vital signs received prehospital crystalloid solu tion alone or crystalloid solution and red cells (standardcare group) before they arrived at a trauma center. Mortality at 30 days was lower in the plasma group than in the standardcare group (23.2% vs. 33.0%, P = 0.03).
7 Transfusion of plasma did not delay the transport time to the trauma center (42 minutes in the plasma group and 40 minutes in the standardcare group), and with the addition of 2 units of plasma, the ratio of plasma to red cells administered in the plasma group was close to 1:1, which is consistent with the principles of damagecontrol resuscitation. Air medical providers from 27 individual bases performed these transfusions safely with very few reported adverse events. Thus, based on the percentagepoint difference in mortality between the two treatment groups, the number of pa tients that would need to be treated for one ad ditional patient to survive (10 patients) favors prehospital plasma, whereas the number of patients that would need to be treated to cause harm cannot be calculated.
Plasma is relatively inexpensive; however, there are some logistic challenges associated with prehospital administration. Plasma requires cold storage and careful monitoring of temperature, and the viable shelf life of the product must also be considered. Freshfrozen plasma that has been thawed, as was used in this trial, has a shelf life of approximately 5 days. This short shelf life re sults in an increased risk of waste and the need for more frequent resupply of inventory. As an alternative, neverfrozen liquid plasma, with its 26day shelf life, mitigates these issues. Freeze dried plasma (not approved by the Food and Drug Administration) does not require cold stor age and has a 2year shelf life, which make it an attractive option for resourcelimited locations and masscasualty situations. Finally, refriger ated whole blood has a shelf life of 21 days and offers the benefit of both platelets and oxygen delivery, making it perhaps the ideal product for prehospital resuscitation. Although these vari ous alternative products are being explored, the PAMPer trial has shown the benefits and safety of prehospital plasma administration, which should motivate trauma center personnel and air medical crews across the country to consider implementing this lifesaving approach.
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